Screener
Asset Entities ASST Medical Device — Net loss
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Asset Entities in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Asset Entities’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054985
| Line item | Successor / Three Months Ended June 30, 2026 | Predecessor / Three Months Ended June 30, 2025 |
|---|---|---|
| Total other income/(expense) | 646 | (5,185) |
| Net loss before income taxes | (257,603) | (8,875) |
| Income tax benefit/(expense) | — | — |
| Net loss | $(257,603) | $(8,875) |
| Dividends on preferred stock | (26,209) | — |
| Net loss attributable to common stockholders | $(283,812) | $(8,875) |
| Weighted average number of common shares outstanding: | ||
| Basic (1) | 75,275,806 | 2,300,998 |
Item 1. Consolidated Financial Statements
FAQ
- What is Asset Entities's medical device — net loss?
- Asset Entities (ASST) reported medical device — net loss of -$4.95M in Q2 2026.
- What does medical device — net loss mean?
- This metric represents the net financial loss generated specifically by the medical device business segment after accounting for all associated operating expenses and costs. It serves as an indicator of the segment's current profitability challenges and the extent to which it requires capital support from the broader organization. Investors use this to evaluate the segment's burn rate and the efficiency of its cost structure relative to its revenue generation.
Ask your AI about Asset Entities's medical device — net loss.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude